JP2024517678A5 - - Google Patents

Info

Publication number
JP2024517678A5
JP2024517678A5 JP2023565327A JP2023565327A JP2024517678A5 JP 2024517678 A5 JP2024517678 A5 JP 2024517678A5 JP 2023565327 A JP2023565327 A JP 2023565327A JP 2023565327 A JP2023565327 A JP 2023565327A JP 2024517678 A5 JP2024517678 A5 JP 2024517678A5
Authority
JP
Japan
Prior art keywords
halo
acetamide
alkyl
propanamide
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023565327A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024517678A (ja
Filing date
Publication date
Priority claimed from EP21170274.1A external-priority patent/EP4079748A1/en
Application filed filed Critical
Publication of JP2024517678A publication Critical patent/JP2024517678A/ja
Publication of JP2024517678A5 publication Critical patent/JP2024517678A5/ja
Pending legal-status Critical Current

Links

JP2023565327A 2021-04-23 2022-04-22 ソルチリン活性の修飾物質 Pending JP2024517678A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21170274.1 2021-04-23
EP21170274.1A EP4079748A1 (en) 2021-04-23 2021-04-23 Modulators of sortilin activity
PCT/EP2022/060742 WO2022223805A1 (en) 2021-04-23 2022-04-22 Modulators of sortilin activity

Publications (2)

Publication Number Publication Date
JP2024517678A JP2024517678A (ja) 2024-04-23
JP2024517678A5 true JP2024517678A5 (https=) 2025-04-21

Family

ID=75674611

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023565327A Pending JP2024517678A (ja) 2021-04-23 2022-04-22 ソルチリン活性の修飾物質

Country Status (8)

Country Link
US (1) US20240217922A1 (https=)
EP (2) EP4079748A1 (https=)
JP (1) JP2024517678A (https=)
KR (1) KR20240000510A (https=)
CN (1) CN117677627A (https=)
AU (1) AU2022260554A1 (https=)
CA (1) CA3215848A1 (https=)
WO (1) WO2022223805A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4361165A1 (en) * 2022-10-24 2024-05-01 Insusense ApS Modulators of sortilin activity
EP4471047A1 (en) * 2023-05-31 2024-12-04 Insusense ApS Modulators of sortilin activity
CN116143648A (zh) * 2022-12-05 2023-05-23 河北远大九孚生物科技有限公司 一种n-乙酰-l-苯丙氨酸的合成方法
EP4428121A1 (en) * 2023-03-07 2024-09-11 Vesper Bio Aps Modulators of sortilin activity
EP4428124A1 (en) * 2023-03-07 2024-09-11 Vesper Bio Aps Modulators of sortilin activity
EP4719366A1 (en) 2023-05-26 2026-04-08 Bertram Wiedenmann Sortilin inhibitors for treatment of patients with functional neuroendocrine tumors
WO2025178062A1 (en) * 2024-02-20 2025-08-28 Otsuka Pharmaceutical Co., Ltd. Piperidine- and morpholine-carboxylate compounds as sort1 inhibitors

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA878158B (en) * 1986-10-31 1989-06-28 Pfizer Nor-statine and nor-cyclostatine polypeptides
DE3842067A1 (de) * 1988-12-14 1990-06-21 Hoechst Ag Enzym-hemmende aminosaeurederivate, verfahren zu ihrer herstellung, diese enthaltende mittel und ihre verwendung
JPH05345754A (ja) * 1992-06-15 1993-12-27 Suntory Ltd ジペプチド誘導体およびそれを有効成分とする骨疾患の予防または治療剤
DE19546532C2 (de) * 1995-12-13 2000-04-20 Degussa Verfahren zur Gewinnung von optisch aktiven L-alpha-Aminocarbonsäuren aus entsprechenden racemischen D,L-alpha-Aminocarbonsäuren
WO2004037159A2 (en) * 2002-10-23 2004-05-06 Obetherapy Biotechnology Compounds, compositions and methods for modulating fat metabolism
WO2006050861A2 (en) * 2004-11-10 2006-05-18 Boehringer Ingelheim International Gmbh Statine derivatives for the treatment of alzheimer's disease
EP1913017A1 (en) * 2005-08-03 2008-04-23 Boehringer Ingelheim International GmbH Substituted ethane-1,2-diamines for the treatment of alzheimer's disease ii
HUE030465T2 (hu) 2009-05-13 2017-05-29 Antivirális vegyületek
GB201011411D0 (en) * 2010-07-06 2010-08-18 St Georges Hosp Medical School Therapeutic compounds and their use
EP2948147B1 (en) * 2013-01-28 2019-03-13 H. Lundbeck A/S N-substituted-5-substituted phthalamic acids as sortilin inhibitors
WO2015131100A1 (en) 2014-02-28 2015-09-03 The Scripps Research Institute Ligand-controlled c(sp3)-h arylation and olefination in synthesis of unnatural chiral alpha amino acids
US20160331746A1 (en) 2015-05-12 2016-11-17 University Of South Florida Sortilin-Binding Small Molecules for Increasing Glucose Uptake

Similar Documents

Publication Publication Date Title
JP2024517678A5 (https=)
JP2024517498A5 (https=)
JP2022185107A5 (https=)
JP2018519323A5 (https=)
RU2003105805A (ru) Производные 4-фенилпиридина в качестве антагонистов рецепторов нейрокинина-1
JP2007502806A5 (https=)
CA2418868A1 (en) 4-phenyl-pyridine derivatives as neurokinin-1 receptor antagonists
JP2021512150A5 (https=)
JP2019518766A5 (https=)
RU2008110949A (ru) Соединения и композиции-иммуносупрессанты
NZ627750A (en) Carbamate compounds and of making and using same
RU2012116877A (ru) Соединения 2-пиридона, применяемые в качестве ингибиторов нейтрофильной эластазы
JP2015516420A5 (https=)
CA2516682A1 (en) Imidazol-4-yl-ethynyl-pyridine derivatives
RU2015111133A (ru) Ингибиторы тирозинкиназы брутона
JP2016515606A5 (https=)
JP2013538801A5 (https=)
CA2601508A1 (en) Cyclopropanecarboxamide derivatives
HRP20220472T1 (hr) Novi derivati heteroarilamida kao selektivni inhibitori histonskih deacetilaza 1 i 2 (hdac1-2)
JP2011526594A5 (https=)
RU2014113679A (ru) N-(2-амино-6,6-дифтор-4,4а,5,6,7,7а-гексагидро-циклопента[e][1,3]оксазин-4-ил)-фенил)-амиды в качестве ингибиторов бета-секретазы 1
JP2017508733A5 (https=)
JP2008508247A5 (https=)
RU2013130879A (ru) Производные оксазолилметилового эфира в качестве агонистов рецептора alx
JP2024537619A5 (https=)